For: | Kanda T, Nakamoto S, Yokosuka O. Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C? World J Virology 2015; 4(3): 178-184 [PMID: 26279979 DOI: 10.5501/wjv.v4.i3.178] |
---|---|
URL: | https://www.wjgnet.com/2220-3249/full/v4/i3/178.htm |
Number | Citing Articles |
1 |
Abdel-Hameed Ibrahim Mohamed Ebid, Ossama Ashraf Ahmed, Sara Hassan Agwa, Sara Mohamed Abdel-Motaleb, Radwa Samir Hagag. Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients. International Journal of Clinical Pharmacy 2020; 42(4): 1207 doi: 10.1007/s11096-020-01085-2
|
2 |
Marwa K. Ibrahim, Mohamed AbdElrahman, Noha G. Bader El Din, Salwa Tawfik, Sherief Abd-Elsalam, Dalia Omran, Amal Z. Barakat, Sally Farouk, Hassan Elbatae, Mostafa K. El Awady. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients. Microbial Pathogenesis 2022; 162: 105311 doi: 10.1016/j.micpath.2021.105311
|
3 |
Victoria Ekstrom, Rajneesh Kumar, Yi Zhao, Mei Ling Yee, Cynthia Sung, Dorothy Toh, Poh Yen Loh, Jessica Tan, Eng Kiong Teo, Wan Cheng Chow. Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourableIL28Bpolymorphism. Gastroenterology Report 2016; : gow033 doi: 10.1093/gastro/gow033
|
4 |
Martina Smolić, Tea Omanović, Ivana Božić, Ines Bilić-Ćurčić, Robert Smolić, Aleksandar Včev. Update on Hepatitis C. 2017; doi: 10.5772/intechopen.70794
|